Frontera Therapeutics递表港交所

Core Viewpoint - Frontera Therapeutics has submitted a listing application to the Hong Kong Stock Exchange, aiming to develop innovative gene therapies with a focus on affordability and effectiveness for patients worldwide [1]. Company Overview - Frontera Therapeutics is a clinical-stage gene therapy company founded in 2019, specializing in the development of innovative therapies [1]. - The company has a global business presence and is dedicated to creating effective and affordable gene therapy solutions for patients around the world [1]. - Frontera Therapeutics has developed a leading pipeline of innovative recombinant adeno-associated virus (itAAV) gene therapies, particularly targeting ophthalmic and cardiovascular diseases [1]. Financial and Advisory Information - UBS Securities Hong Kong Limited and Haitong International Capital Limited are acting as joint sponsors for Frontera Therapeutics' listing application [1].